There is alarming rise in cases of dermatophytosis in India. Standard treatment recommendations are no longer working. Combination of topical and systemic antifungal drugs is one of the most frequently used treatment strategy. Materials and Methods: This was an open label, prospective, interventional, non-comparative study. Effectiveness endpoints were percentage of patients achieving complete cure, clinical cure and mycological cure at the end of the treatment period from baseline. Safety was assessed by analyzing the AEs and monitoring of liver function tests. Results: 66 patients were included in the study. 75.75%, 86.36% and 81.8% patients achieved complete cure, clinical cure and mycological cure respectively at the end of the study period. There was improvement in each symptom during study duration as observed during each follow up visit on week 2, 4 and 6. Total of 10.60% reported 1 or more drug related AE. Nausea was most common side effect followed by vomiting, headache and edema of face. All the AEs were mild in nature and resolved during study. Conclusion:To conclude the result of this study shows that the combination therapy of oral itraconazole and topical amorolfine represents an improved treatment strategy for patients with recalcitrant multisite tinea infections.
Introduction: Chronic urticaria consists of itchy rash on most days for at least six weeks. It is caused by release of histamine and other mediators from degranulated cutaneous mast cells. Antihistamines, the current treatment mainstay, do not provide relief in many cases and necessitates the use of adjunctive treatment. Histaglobin, through the synthesis of histamine-neutralizing antibodies, can serve as an adjunct. The current study was aimed to evaluate the efficacy and safety of Histaglobin, as adjunctive therapy, in patients with chronic urticaria. Materials and Methods: Patients with chronic urticaria were enrolled in this single-centre, prospective open-label study. Patients were administered 3 injections of Histaglobin (1ml), subcutaneously, at intervals of 7 days. Efficacy was assessed by grading the change in disease activity, measured using urticarial activity score (UAS 7) on days 0, 7, 14, 28 and 42. Adverse events (AEs) and concomitant medications were also recorded at each study visit. Results: Thirty-seven of the 38 enrolled patients completed study by following-up on day 28. Thirtyfour (91.9%) patients showed improvement; 21 (56.8%) showed 'moderate improvement' and 13(35.1%) showed 'clear cut improvement'. There was a significant (p<0.0001) reduction in UAS from Day 0(15.8 ±6.1) to Day 28(6.0±6.2). There was one patient who developed redness at injection site. Half the patients on antihistamines and all those on steroid treatment were able to reduce/stop these treatments at the end of study. Conclusion: Histaglobin treatment was found to be effective in the treatment of chronic urticaria. It was also well tolerated and reduced antihistamines and steroids pill burden. Histaglobin, is a safe, well-tolerated and valuable adjunct to antihistamines in the management of chronic urticaria.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.